Patidegib

Drug Overview

Patidegib is a highly specialized, experimental cancer medication. It belongs to an advanced group of medicines known as Targeted Therapy. While it was originally tested as a pill, scientists have recently reformulated it into a topical gel. This gel is designed to be applied directly to the skin to treat and prevent skin cancers, specifically in patients with a rare genetic condition called Gorlin syndrome. Because it is still being tested in clinical trials, it is not yet available at your local pharmacy.

• Generic Name: Patidegib (also known in research as saridegib, IPI-926, or SGT-610)
• US Brand Names: None (Experimental drug)
• Drug Class: Smoothened (SMO) Inhibitor / Hedgehog Pathway Inhibitor (Targeted Therapy)
• Route of Administration: Topical (Applied as a gel to the skin). Historically tested as an oral pill.
• FDA Approval Status: Not FDA Approved. (It is currently strictly limited to clinical trials, though it has been granted “Orphan Drug” and “Breakthrough Therapy” designations by the FDA to speed up research).

What Is It and How Does It Work? (Mechanism of Action)

Patidegib is a Targeted Therapy designed to fix a broken communication signal inside skin cells. To understand how it works at the molecular level, it helps to look at how cells get their instructions to grow.

Inside human cells, there is a communication network called the “Hedgehog (HH) signaling pathway.” You can think of this pathway as a relay race that tells the cell when to divide and grow. In healthy cells, a protein called PTCH1 acts like a “brake” to keep this pathway turned off when cell growth is not needed.

In patients with Gorlin syndrome or Basal Cell Carcinomas (BCCs), the PTCH1 brake is broken due to a genetic mutation. Because the brake is missing, another protein called Smoothened (SMO) acts like a stuck gas pedal. It constantly sends signals to the cell’s core, forcing the skin cells to multiply out of control and form tumors.

Here is how patidegib works:

• The Blockade: Patidegib physically binds directly to the hyperactive SMO protein.
• Stopping the Signal: By attaching to SMO, the drug successfully takes the foot off the “gas pedal.” It completely shuts down the broken Hedgehog signaling pathway.
• The Result: Without these constant growth signals, the skin cancer cells stop dividing. By applying the medicine directly to the skin as a gel, the drug targets the tumors right where they start without flooding the rest of the body with the medication.

FDA-Approved Clinical Indications

Because patidegib is an experimental medicine, it has not received full approval from the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general public use.

Oncological Uses (Investigational Only):

• Gorlin Syndrome (also known as Basal Cell Nevus Syndrome) to prevent the development of new facial Basal Cell Carcinomas (BCCs).
• Sporadic (randomly occurring) Basal Cell Carcinomas.

Non-oncological Uses:

• None at this time.

Dosage and Administration Protocols

Because patidegib is currently being tested in Phase 3 clinical trials, the dose is based on strict study rules. The information below reflects how the drug is administered in current major trials for Gorlin syndrome.

Note: Individual dosing instructions are highly specific to the clinical trial rules and must be followed exactly as the study doctor prescribes.

Clinical Efficacy and Research Results

Recent clinical studies (published between 2023 and 2025) have focused on the 2% topical gel formulation of patidegib. Researchers designed the gel to treat skin cancer effectively without causing the harsh full-body side effects seen with older oral (pill) versions of Hedgehog inhibitors.

• Tumor Prevention: In Phase 2 and early Phase 3 trial analyses, applying the 2% gel twice a day successfully reduced the Hedgehog growth signals in the skin.
• Disease Progression: For patients with Gorlin syndrome, the primary goal is to prevent new skin cancers from forming so patients do not need constant surgeries. In specific trial analyses looking at patients with the exact PTCH1 genetic mutation and a high number of facial tumors, the patidegib gel reduced the formation of new facial Basal Cell Carcinomas by up to 50% over a 12-month period.
• Systemic Safety: Blood tests during these recent trials proved that when the drug is applied as a gel, the amount of medicine that enters the bloodstream is extremely low. This means the drug works locally on the skin while keeping the rest of the body safe.

Safety Profile and Side Effects

Like all medicines, patidegib can cause side effects. However, because the new formulation is a topical gel, its side effect profile is much gentler than older targeted therapy pills.

Black Box Warning:

There is currently no FDA “Black Box Warning” because the drug is experimental and unapproved.

Common Side Effects (Occurs in >10% of patients)

• Skin redness at the application site (Erythema)
• Dry, flaking, or scaling skin on the face
• Mild itching or burning where the gel is rubbed in

Serious Adverse Events

• Systemic Side Effects (Rare with Gel, Common with Pills): In historical trials where patidegib was taken as an oral pill, it caused severe muscle spasms, hair loss (alopecia), and a complete loss of the sense of taste (dysgeusia). The modern topical gel was created specifically to avoid these serious issues, and they are rarely seen in current gel trials.
• Severe Skin Irritation: In rare cases, the skin can become highly inflamed, resembling a severe sunburn or allergic reaction.

Management Strategies

• For Skin Dryness and Irritation: Trial doctors encourage patients to use gentle, fragrance-free moisturizers and emollients on their face to protect the skin barrier.
• For Severe Rashes: If the skin becomes too raw or painful, the study doctor may ask the patient to pause the gel for a few days until the skin heals.

Connection to Stem Cell and Regenerative Medicine

The science behind patidegib is deeply connected to regenerative medicine and stem cell biology. The Hedgehog signaling pathway—which this drug blocks—is actually a normal, healthy pathway that embryos use to grow in the womb. In adults, this pathway is mostly turned off, but it remains slightly active in certain “adult stem cells,” such as the stem cells found in hair follicles that help repair damaged skin. In Gorlin syndrome, a genetic mistake causes these hair follicle stem cells to become permanently stuck in the “on” position, driving them to form tumors instead of healthy skin. By studying how drugs like patidegib control the Hedgehog pathway, scientists are learning vital lessons about how to safely command stem cells to heal tissues without accidentally causing cancer.

Patient Management and Practical Recommendations

To keep patients safe and ensure the clinical trial data is accurate, healthcare teams follow strict rules for patients using patidegib gel.

Pre-treatment Tests to be Performed

• Genetic Testing: A blood or saliva test to confirm the patient has a PTCH1 gene mutation (the genetic cause of Gorlin syndrome).
• Baseline Skin Mapping: A dermatologist will carefully count, measure, and photograph all existing skin cancers on the face before the trial begins.

Precautions During Treatment

• Sun Protection: Patients must avoid excessive sun exposure. Wearing a broad-spectrum sunscreen (SPF 30 or higher) and a wide-brimmed hat daily is absolutely required.
• Pregnancy Prevention: Because the Hedgehog pathway is involved in fetal growth, blocking it can cause severe birth defects. Female patients must use highly effective birth control, and male patients must use condoms, during the trial.

“Do’s and Don’ts” List

• DO wash your hands thoroughly with soap and water immediately after applying the gel to your face.
• DO apply the gel to a clean, dry face, and wait at least a few minutes before applying your daily moisturizer or sunscreen.
• DO attend all of your scheduled skin check appointments so your doctor can track any new tumors.
• DON’T apply any other medicated acne creams, anti-aging retinols, or over-the-counter prescription creams to your face without asking your study doctor first.
• DON’T apply the gel directly into your eyes, nose, or mouth.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Patidegib (SGT-610) is an investigational drug and is not approved by the FDA, EMA, or other global regulatory bodies for commercial use outside of clinical trials. Always consult with your oncologist or a qualified dermatologist regarding your specific medical condition, genetic testing, clinical trial eligibility, and available, approved treatment options.